Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786622 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2ADORA1ADORA2AKDM4E | |
| SCHEMBL4451017 | 0.74 | ALDH1A1 (0.51) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL29794067 | 0.72 | ADORA2A (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL10330164 | 0.72 | ADORA2A (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL10329726 | 0.72 | ADORA2A (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL2788919 | 0.71 | GRM1 (0.50) | ALDH1A1RAB9ASMN1; SMN2NPC1SRC | |
| SCHEMBL28678286 | 0.70 | ADORA2A (0.55) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL16014509 | 0.69 | CNR2 (0.51) | ALDH1A1ADORA1ADORA2AKDM4ECNR2 | |
| SCHEMBL5972006 | 0.69 | ADORA1 (0.66) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL27566640 | 0.67 | RECQL (0.69) | ALDH1A1RAB9ASMN1; SMN2NPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1349552-B1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
| EP-1349552-A1 | PYRAZOLO 3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055082-A1 | PYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | CHRNA6, CHRNA5, CNR1 | ALDH1A1 2224/4885RAB9A 1355/4885SMN1; SMN2 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.